Short Interest in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Increases By 27.3%

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) was the target of a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 439,335 shares, a growth of 27.3% from the January 15th total of 345,021 shares. Based on an average daily trading volume, of 174,125 shares, the short-interest ratio is presently 2.5 days. Currently, 1.1% of the shares of the company are sold short. Currently, 1.1% of the shares of the company are sold short. Based on an average daily trading volume, of 174,125 shares, the short-interest ratio is presently 2.5 days.

Institutional Trading of MIRA Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its holdings in MIRA Pharmaceuticals by 100.0% in the fourth quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock valued at $412,000 after buying an additional 136,438 shares in the last quarter. First American Bank increased its stake in shares of MIRA Pharmaceuticals by 20.0% in the 4th quarter. First American Bank now owns 60,000 shares of the company’s stock valued at $91,000 after purchasing an additional 10,000 shares in the last quarter. Two Sigma Investments LP raised its holdings in MIRA Pharmaceuticals by 129.8% in the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock worth $62,000 after purchasing an additional 25,816 shares during the period. International Assets Investment Management LLC purchased a new position in MIRA Pharmaceuticals during the second quarter worth approximately $42,000. Finally, Creative Planning acquired a new stake in MIRA Pharmaceuticals in the second quarter valued at approximately $27,000. Institutional investors and hedge funds own 35.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen lowered shares of MIRA Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Finally, Rodman & Renshaw initiated coverage on shares of MIRA Pharmaceuticals in a report on Tuesday, January 13th. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

MIRA Pharmaceuticals Price Performance

MIRA stock traded down $0.02 during trading on Monday, hitting $1.16. 56,422 shares of the company traded hands, compared to its average volume of 152,552. MIRA Pharmaceuticals has a 1 year low of $0.73 and a 1 year high of $2.45. The company has a market cap of $48.58 million, a PE ratio of -0.76 and a beta of 1.80. The stock’s 50-day simple moving average is $1.41 and its 200 day simple moving average is $1.43.

MIRA Pharmaceuticals (NASDAQ:MIRA) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($1.07). Research analysts expect that MIRA Pharmaceuticals will post -0.6 earnings per share for the current year.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.